Lupin, one of the leading pharmaceutical companies in India, has incorporated a wholly-owned subsidiary in the USA under the name ‘Lupin Oncology Inc.' (LOI).

This wholly owned subsidiary will be engaged in development/co-development and commercialization of multiple oncology products globally. LOI will be pursuing partners, financial sponsors and perform such other acts as may be necessary, the company said.

Shares of the company gained Rs 17.7, or 1.67%, to settle  at  Rs 1,079.  The total volume of shares traded  was  243,642 at  the BSE (Friday).